{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T20:04:08Z","timestamp":1762459448736,"version":"3.41.0"},"reference-count":53,"publisher":"Oxford University Press (OUP)","issue":"5","funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000061","name":"Fogarty International Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000061","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Office of Global AIDS Coordinator and the U. S. Department of Health and Human Services, National Institutes of Health (NIH OAR and NIH OWAR)","award":["5R24TW008863"],"award-info":[{"award-number":["5R24TW008863"]}]},{"name":"the European & Developing Countries Clinical Trials Partnership (EDCTP)","award":["TA.2011.40200.044"],"award-info":[{"award-number":["TA.2011.40200.044"]}]},{"name":"National Research Foundation of South Africa","award":["90729"],"award-info":[{"award-number":["90729"]}]},{"name":"Columbia University-South Africa Fogarty AIDS260 International Training and Research Program","award":["D43TW000231"],"award-info":[{"award-number":["D43TW000231"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,5,1]]},"DOI":"10.1093\/jac\/dkx004","type":"journal-article","created":{"date-parts":[[2017,1,4]],"date-time":"2017-01-04T20:07:09Z","timestamp":1483560429000},"page":"1441-1449","source":"Crossref","is-referenced-by-count":38,"title":["Effect of rifampicin and efavirenz on moxifloxacin concentrations when co-administered in patients with drug-susceptible TB"],"prefix":"10.1093","volume":"72","author":[{"given":"Anushka","family":"Naidoo","sequence":"first","affiliation":[{"name":"Centre for the AIDS Programme of Research in South Africa (CAPRISA), University of KwaZulu-Natal, Durban, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maxwell","family":"Chirehwa","sequence":"additional","affiliation":[{"name":"Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helen","family":"McIlleron","sequence":"additional","affiliation":[{"name":"Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kogieleum","family":"Naidoo","sequence":"additional","affiliation":[{"name":"Centre for the AIDS Programme of Research in South Africa (CAPRISA), University of KwaZulu-Natal, Durban, South Africa"},{"name":"MRC-CAPRISA HIV-TB Pathogenesis and Treatment Research Unit, Doris Duke Medical Research Institute, University of KwaZulu-Natal"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabiha","family":"Essack","sequence":"additional","affiliation":[{"name":"Antimicrobial Research Unit, School of Health Sciences, University of KwaZulu-Natal, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nonhlanhla","family":"Yende-Zuma","sequence":"additional","affiliation":[{"name":"Centre for the AIDS Programme of Research in South Africa (CAPRISA), University of KwaZulu-Natal, Durban, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eddy","family":"Kimba-Phongi","sequence":"additional","affiliation":[{"name":"Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Adamson","sequence":"additional","affiliation":[{"name":"KwaZulu-Natal Research Institute for Tuberculosis and HIV, Durban, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katya","family":"Govender","sequence":"additional","affiliation":[{"name":"KwaZulu-Natal Research Institute for Tuberculosis and HIV, Durban, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nesri","family":"Padayatchi","sequence":"additional","affiliation":[{"name":"Centre for the AIDS Programme of Research in South Africa (CAPRISA), University of KwaZulu-Natal, Durban, South Africa"},{"name":"MRC-CAPRISA HIV-TB Pathogenesis and Treatment Research Unit, Doris Duke Medical Research Institute, University of KwaZulu-Natal"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Denti","sequence":"additional","affiliation":[{"name":"Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2017,2,8]]},"reference":[{"year":"2016","author":"WHO","key":"key\n\t\t\t\t20180313122408_dkx004-B1"},{"key":"key\n\t\t\t\t20180313122408_dkx004-B2","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1183\/16000617.0080-2015","article-title":"Short-course treatment for multidrug-resistant tuberculosis: the STREAM trials","volume":"25","author":"Moodley","year":"2016","journal-title":"Eur Respir Rev"},{"key":"key\n\t\t\t\t20180313122408_dkx004-B3","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1016\/S0140-6736(14)62002-X","article-title":"Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis","volume":"385","author":"Dawson","year":"2015","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20180313122408_dkx004-B4","first-page":"1","article-title":"Moxifloxacin: an alternative to ethambutol for the treatment of presumed ocular tuberculosis","volume":"24","author":"Potter","year":"2015","journal-title":"Ocul Immunol Inflamm"},{"year":"2015","author":"WHO","key":"key\n\t\t\t\t20180313122408_dkx004-B5"},{"key":"key\n\t\t\t\t20180313122408_dkx004-B6","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1128\/AAC.01377-15","article-title":"Treatment outcomes with fluoroquinolone-containing regimens for isoniazid-resistant pulmonary tuberculosis","volume":"60","author":"Lee","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180313122408_dkx004-B7","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1056\/NEJMoa1407426","article-title":"Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis","volume":"371","author":"Gillespie","year":"2014","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180313122408_dkx004-B8","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1056\/NEJMoa1314210","article-title":"High-dose rifapentine with moxifloxacin for pulmonary tuberculosis","volume":"371","author":"Jindani","year":"2014","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180313122408_dkx004-B9","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S1473-3099(14)70885-0","article-title":"Shortening treatment of tuberculosis: lessons from fluoroquinolone trials","volume":"15","author":"Nimmo","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"key\n\t\t\t\t20180313122408_dkx004-B10","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1056\/NEJMra1413919","article-title":"Treatment of tuberculosis","volume":"373","author":"Horsburgh","year":"2015","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180313122408_dkx004-B11","doi-asserted-by":"crossref","first-page":"576.","DOI":"10.1056\/NEJMc1414718","article-title":"Shorter moxifloxacin-based regimens for drug-sensitive tuberculosis","volume":"372","author":"Alffenaar","year":"2015","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180313122408_dkx004-B12","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1086\/521894","article-title":"Rifampicin reduces plasma concentrations of moxifloxacin in patients with tuberculosis","volume":"45","author":"Nijland","year":"2007","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180313122408_dkx004-B13","doi-asserted-by":"crossref","first-page":"2861","DOI":"10.1128\/AAC.01621-06","article-title":"Effects of rifampin and multidrug resistance gene polymorphism on concentrations of moxifloxacin","volume":"51","author":"Weiner","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180313122408_dkx004-B14","first-page":"979","article-title":"Effect of rifampicin & isoniazid on the steady state pharmacokinetics of moxifloxacin","volume":"136","author":"Ramachandran","year":"2012","journal-title":"Indian J Med Res"},{"key":"key\n\t\t\t\t20180313122408_dkx004-B15","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.5588\/ijtld.14.0935","article-title":"Rifampicin-moxifloxacin interaction in tuberculosis treatment: a real-life study","volume":"19","author":"Manika","year":"2015","journal-title":"Int J Tuberc Lung Dis"},{"key":"key\n\t\t\t\t20180313122408_dkx004-B16","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/clpt.2010.271","article-title":"Rifampin's acute inhibitory and chronic inductive drug interactions: experimental and model-based approaches to drug-drug interaction trial design","volume":"89","author":"Reitman","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"key\n\t\t\t\t20180313122408_dkx004-B17","doi-asserted-by":"crossref","first-page":"4122","DOI":"10.1128\/AAC.01833-10","article-title":"The SLCO1B1 rs4149032 polymorphism is highly prevalent in South Africans and is associated with reduced rifampin concentrations: dosing implications","volume":"55","author":"Chigutsa","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180313122408_dkx004-B18","doi-asserted-by":"crossref","first-page":"987","DOI":"10.3855\/jidc.4696","article-title":"Low rifampicin concentrations in tuberculosis patients with HIV infection","volume":"8","author":"Gengiah","year":"2014","journal-title":"J Infect Dev Ctries"},{"key":"key\n\t\t\t\t20180313122408_dkx004-B19","doi-asserted-by":"crossref","first-page":"108291.","DOI":"10.1155\/2014\/108291","article-title":"Genetics of sub-Saharan African human population: implications for HIV\/AIDS, tuberculosis, and malaria","volume":"2014","author":"Mboowa","year":"2014","journal-title":"Int J Evol Biol"},{"key":"key\n\t\t\t\t20180313122408_dkx004-B20","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2165\/00003088-200140001-00006","article-title":"Evaluation of the influence of antacids and H2 antagonists on the absorption of moxifloxacin after oral administration of a 400mg dose to healthy volunteers","volume":"40","author":"Stass","year":"2001","journal-title":"Clin Pharmacokinet"},{"key":"key\n\t\t\t\t20180313122408_dkx004-B21","doi-asserted-by":"crossref","first-page":"57","DOI":"10.2165\/00003088-200140001-00008","article-title":"Effects of iron supplements on the oral bioavailability of moxifloxacin, a novel 8-methoxyfluoroquinolone, in humans","volume":"40","author":"Stass","year":"2001","journal-title":"Clin Pharmacokinet"},{"author":"FDA","key":"key\n\t\t\t\t20180313122408_dkx004-B22"},{"volume-title":"NONMEM Users Guides (1989-2009)","year":"2009","author":"Beal","key":"key\n\t\t\t\t20180313122408_dkx004-B23"},{"key":"key\n\t\t\t\t20180313122408_dkx004-B24","doi-asserted-by":"crossref","first-page":"e50.","DOI":"10.1038\/psp.2013.24","article-title":"Modeling and simulation workbench for NONMEM: tutorial on Pirana, PsN, and Xpose","volume":"2","author":"Keizer","year":"2013","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"volume-title":"R: A Language and Environment for Statistical Computing","year":"2014","author":"R Core Team","key":"key\n\t\t\t\t20180313122408_dkx004-B25"},{"volume-title":"RStudio: Integrated Development Environment for R","year":"2015","author":"RStudio Team","key":"key\n\t\t\t\t20180313122408_dkx004-B26"},{"key":"key\n\t\t\t\t20180313122408_dkx004-B27","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/j.1365-2125.2004.02321.x","article-title":"A semiphysiological pharmacokinetic model for artemisinin in healthy subjects incorporating autoinduction of metabolism and saturable first-pass hepatic extraction","volume":"59","author":"Gordi","year":"2005","journal-title":"Br J Clin Pharmacol"},{"key":"key\n\t\t\t\t20180313122408_dkx004-B28","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1517\/13543784.8.2.181","article-title":"Moxifloxacin (Bay 12-8039): a new methoxy quinolone antibacterial","volume":"8","author":"MacGowan","year":"1999","journal-title":"Expert Opin Investig Drugs"},{"year":"2002","author":"Cato","key":"key\n\t\t\t\t20180313122408_dkx004-B29"},{"key":"key\n\t\t\t\t20180313122408_dkx004-B30","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s10928-007-9066-0","article-title":"Implementation of a transit compartment model for describing drug absorption in pharmacokinetic studies","volume":"34","author":"Savic","year":"2007","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"key\n\t\t\t\t20180313122408_dkx004-B31","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1023\/A:1012299115260","article-title":"Ways to fit a PK model with some data below the quantification limit","volume":"28","author":"Beal","year":"2001","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"key\n\t\t\t\t20180313122408_dkx004-B32","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1146\/annurev.pharmtox.48.113006.094708","article-title":"Mechanism-based concepts of size and maturity in pharmacokinetics","volume":"48","author":"Anderson","year":"2008","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"key\n\t\t\t\t20180313122408_dkx004-B33","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.2165\/00003088-200544100-00004","article-title":"Quantification of lean bodyweight","volume":"44","author":"Janmahasatian","year":"2005","journal-title":"Clin Pharmacokinet"},{"year":"2005","author":"Holford","key":"key\n\t\t\t\t20180313122408_dkx004-B34"},{"key":"key\n\t\t\t\t20180313122408_dkx004-B35","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1128\/AAC.01478-13","article-title":"Moxifloxacin population pharmacokinetics and model-based comparison of efficacy between moxifloxacin and ofloxacin in African patients","volume":"58","author":"Zvada","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180313122408_dkx004-B36","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1183\/09031936.00176610","article-title":"Evaluation of moxifloxacin for the treatment of tuberculosis: 3 years of experience","volume":"38","author":"Pranger","year":"2011","journal-title":"Eur Respir J"},{"key":"key\n\t\t\t\t20180313122408_dkx004-B37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00003088-200140001-00001","article-title":"Pharmacokinetics, safety and tolerability of moxifloxacin, a novel 8-methoxyfluoroquinolone, after repeated oral administration","volume":"40","author":"Stass","year":"2001","journal-title":"Clin Pharmacokinet"},{"key":"key\n\t\t\t\t20180313122408_dkx004-B38","doi-asserted-by":"crossref","first-page":"851","DOI":"10.3390\/molecules17010851","article-title":"Effect of efavirenz on UDP-glucuronosyltransferase 1A1, 1A4, 1A6, and 1A9 activities in human liver microsomes","volume":"17","author":"Ji","year":"2012","journal-title":"Molecules"},{"key":"key\n\t\t\t\t20180313122408_dkx004-B39","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1007\/s00228-014-1732-8","article-title":"Effects of enzyme inducers efavirenz and tipranavir\/ritonavir on the pharmacokinetics of the HIV integrase inhibitor dolutegravir","volume":"70","author":"Song","year":"2014","journal-title":"Eur J Clin Pharmacol"},{"key":"key\n\t\t\t\t20180313122408_dkx004-B40","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1177\/1545109712454454","article-title":"Factors associated with reduced antituberculous serum drug concentrations in patients with HIV-TB coinfection","volume":"11","author":"Ahmed","year":"2012","journal-title":"J Int Assoc Physicians AIDS Care (Chic)"},{"key":"key\n\t\t\t\t20180313122408_dkx004-B41","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1086\/599040","article-title":"Isoniazid, rifampin, ethambutol, and pyrazinamide pharmacokinetics and treatment outcomes among a predominantly HIV-infected cohort of adults with tuberculosis from Botswana","volume":"48","author":"Chideya","year":"2009","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180313122408_dkx004-B42","doi-asserted-by":"crossref","first-page":"e0141002","DOI":"10.1371\/journal.pone.0141002","article-title":"Pharmacokinetics of isoniazid, pyrazinamide, and ethambutol in newly diagnosed pulmonary TB patients in Tanzania","volume":"10","author":"Denti","year":"2015","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t20180313122408_dkx004-B43","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1128\/AAC.01036-07","article-title":"Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis","volume":"52","author":"Peloquin","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180313122408_dkx004-B44","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1086\/605576","article-title":"Pharmacokinetics of moxifloxacin in cerebrospinal fluid and plasma in patients with tuberculous meningitis","volume":"49","author":"Alffenaar","year":"2009","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180313122408_dkx004-B45","doi-asserted-by":"crossref","first-page":"4471","DOI":"10.1128\/AAC.00404-12","article-title":"Moxifloxacin population pharmacokinetics in patients with pulmonary tuberculosis and the effect of intermittent high-dose rifapentine","volume":"56","author":"Zvada","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180313122408_dkx004-B46","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S1473-3099(12)70264-5","article-title":"Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: an open-label, randomised controlled phase 2 trial","volume":"13","author":"Ruslami","year":"2013","journal-title":"Lancet Infect Dis"},{"key":"key\n\t\t\t\t20180313122408_dkx004-B47","doi-asserted-by":"crossref","first-page":"e0154778","DOI":"10.1371\/journal.pone.0154778","article-title":"A phase 2 randomized trial of a rifapentine plus moxifloxacin-based regimen for treatment of pulmonary tuberculosis","volume":"11","author":"Conde","year":"2016","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t20180313122408_dkx004-B48","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1183\/09031936.00202411","article-title":"Moxifloxacin in multidrug-resistant tuberculosis: is there any indication for therapeutic drug monitoring?","volume":"40","author":"Manika","year":"2012","journal-title":"Eur Respir J"},{"key":"key\n\t\t\t\t20180313122408_dkx004-B49","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1097\/FTD.0b013e31821b793c","article-title":"Limited-sampling strategies for therapeutic drug monitoring of moxifloxacin in patients with tuberculosis","volume":"33","author":"Pranger","year":"2011","journal-title":"Ther Drug Monit"},{"key":"key\n\t\t\t\t20180313122408_dkx004-B50","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1086\/598192","article-title":"Isoniazid plasma concentrations in a cohort of South African children with tuberculosis: implications for international pediatric dosing guidelines","volume":"48","author":"McIlleron","year":"2009","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180313122408_dkx004-B51","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1111\/j.1365-2125.1991.tb03971.x","article-title":"Population pharmacokinetics: theory and practice","volume":"32","author":"Aarons","year":"1991","journal-title":"Br J Clin Pharmacol"},{"key":"key\n\t\t\t\t20180313122408_dkx004-B52","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.ijantimicag.2014.04.019","article-title":"Population pharmacokinetics and limited sampling strategy for first-line tuberculosis drugs and moxifloxacin","volume":"44","author":"Magis-Escurra","year":"2014","journal-title":"Int J Antimicrob Agents"},{"key":"key\n\t\t\t\t20180313122408_dkx004-B53","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1097\/FPC.0b013e32835a450b","article-title":"Genome-wide association study of plasma efavirenz pharmacokinetics in AIDS Clinical Trials Group protocols implicates several CYP2B6 variants","volume":"22","author":"Holzinger","year":"2012","journal-title":"Pharmacogenet Genomics"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/72\/5\/1441\/24332194\/dkx004.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T00:23:09Z","timestamp":1749860589000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/72\/5\/1441\/2975595"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,8]]},"references-count":53,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2017,2,8]]},"published-print":{"date-parts":[[2017,5,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkx004","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"type":"print","value":"0305-7453"},{"type":"electronic","value":"1460-2091"}],"subject":[],"published-other":{"date-parts":[[2017,5]]},"published":{"date-parts":[[2017,2,8]]}}}